Ferrer links with Ildong and Ergomed for lorediplon development

Privately-held Spanish drugmaker Ferrer has executed two agreements, one with South Korea’s Ildong Pharmaceuticals and the other with Ergomed Clinical Research of the UK to support further clinical studies of lorediplon in patients with insomnia.

Under the terms of the Ildong accord, Ferrer will be eligible to receive payments from the cooperation and license agreement covering countries within East Asia, including South Korea, China and Japan. Ildong will be responsible for the costs and activities related to development and regulatory approvals in their territory.

Ferrer selected Ergomed as the clinical development organization to conduct the multicenter, multinational, randomized Phase IIa lorediplon trial in insomnia. Under the terms of the deal, Ergomed will assume a proportion of the clinical and regulatory costs of the Phase IIa trial in return for a share of future revenues received by Ferrer for lorediplon in this indication.

First Ferrer CNS product to enter clinical trial